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European Medicines Agency (EMEA) and the Committee on Herbal Medicinal Products (HMPC) on July 2006 have released an
alert to get European sanitary authorities aware of 42 cases of suspected hepatotoxic reactions in patients consuming Cimicifuga
racemosa rhizome. In the public statement EMEA itself considered reliable as hepatotoxic reactions only four cases, on the base
of RUCAM score: two were considered possible and two probable. Lacking in almost all of them a precise description of cases,
especiallyabotanical-chemical analysisofthesuspectedsubstance,wethinkthereisnorealproofofsupposed C.racemosarhizome
hepatotoxicity. In our department we administer from about 10 years C. racemosa as special herbal dry extract as single substance
or mixed with other medicinal plants at the dose of 500–1000mg daily, for treatment of menopause related disorders without any
reported adverse eﬀect. After EMEA’s oﬃcial signal we have contacted all our patients using a C. racemosa rhizome herbal extract
continuously from more than 12 months to verify possible hepatotoxic eﬀects. We followed-up 107 women, and asked them by
telephone (33/107) and/or after anamnesis and clinical examination (74/107) to undergo a blood sample examination. In all the
patients there was no sign of hepatic disease, or worsening of already altered but stable parameters. We think on the base of these
data and current literature C. racemosa rhizome extract should not be considered a potential hepatotoxic substance.
1.Introduction
Currently hormone replacement therapy (HRT) is com-
monly used to reverse symptoms and diseases associated
withfallingoestrogenandprogesteronelevels.HoweverHRT
is associated with adverse eﬀects and an increased risk of
breast cancer [1]. Many women therefore take a dislike to
HRT and choose to employ herbal remedies for menopausal
symptoms, one of most used worldwide is Black Cohosh.
Cimicifuga racemosa Nuttal (syn. Actaea racemosa L)
common name Black Cohosh (Ranunculaceae; Figure 1),
is an herbaceous perennial plant of North America. It
is a coarse, perennial, woodland herb with large com-
pounds leaves, and a thick, knotted, rhizome system [2].
Traditionally it was used by Native Americans (Penobscot,
Winnebago and Dakota) [3] for the treatment of coughs,
colds, constipation, fatigue and rheumatism and to stimulate
lactation. Since 1832 a hydroalcoholic extract was described
as treatment for pain and inﬂammation in endometriosis
and dysmenorrhea [3]; and a ﬂuid extract was listed in the
US National Formulary from 1840 until 1946 [4]; and was
a major constituent of the once popular patent medicine
“Lydia Pinkham’s Vegetable Compound” used for treatment
of “painful complaints and weakness” in females. Actually,
C. racemosa is widely employed in various pharmaceutical–
industrial preparations often mixed with other medici-
nal plants to alleviate menopausal and post-menopausal
symptoms, including hot ﬂushes, profuse sweating, sleep
disturbances, anxiety and depression.
Safety data from post-marketing surveillance study have
generally found very few serious adverse events, nevertheless
the lack of placebo or positive control arms in main studies,
the lack of serious adverse events suggests that C. racemosa
has a very good safety proﬁle [4]a sc o n ﬁ r m e di nar e v i e wo f
more than 3800 climateric women [5].
Recently the European Medicines Agency (EMEA) and
the Committee on Herbal Medicinal Products (HMPC) on
July 2006 have released a public statement [6], although2 Evidence-Based Complementary and Alternative Medicine
Figure 1: Cimicifuga racemosa Nuttal.
lacking of many data on patients and herbal extracts, to
get European sanitary authorities aware of 42 (34 directly
reported from European national competent authorities
and 8 published) cases of suspected hepatotoxic reactions
in patients, probably all women and for treatment of
menopause related disorders, consuming C. racemosa often
mixed with other medicinal plants. Following the review
of available data, the statement considered real a potential
connection between herbal medicinal products containing
C. racemosa and human hepatotoxic reaction. Nevertheless
this highly authoritative review of such a number of cases,
in the summary EMEA states that “overall, all discussed
cases of literature and pharmacovigilance reports are poorly
documented. In many cases there is not even informa-
tion about the time frame of treatment with Cimicifuga
containing products or about the relation to the onset of
reaction available. Therefore, they are insuﬃciently docu-
mented according to RUCAM score. The Non-EU cases are
not validated by a health care professional but reported
by patients” [6]. Because C. racemosa extracts are sold
as OTC integrators, Italian sanitary authorities decided a
precautionary withdrawal from the national market, that
later has been reversed, and stringent label warnings have
beenintroducedforC.racemosaextractsinUnitedKingdom.
So actually there are some concerns about C. racemosa
extracts safety especially in patients suﬀering of liver
disease.
2. Methods
2.1. Participants. In our department we administer C. race-
mosa rhizome extract regularly for treatment of menopause
related complaints, from about 10 years to 798 patients as
only substance or mixed with other medicinal plants like
Glycine max isoﬂavones, Trifolium pratense and. Medicago
sativa, at the dose of 500 or 1000mg daily as dry extract,
standardized and titrated in 2.5% of actein, a triterpene
glyocoside (Figure 2), for treatment of menopause related
disorders like anxiety, depression, ﬂashes and myalgia. We
regularlyexcludefromthetreatmentpatientsaﬀectedbycan-
cer of sexual organs: breast, ovaries, uterus and hypophysis,
unless already treated with conventional therapy from more
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Figure 2: The main constituents of Black Cohosh.
than 7 years and considered recovered. In our experience we
had no report of adverse reaction to C. racemosa extracts,
bothassingleprescriptioneithermixedwithothermedicinal
plants extracts, but minor complaints.
After EMEA’s oﬃcial statement indicating a possible risk
ofhepatotoxicityinpatientsassumingextractofC.racemosa,
we have contacted all our available patients consuming the
extract continuously from at least 12 months.
So we considered 158 patients eligible, for control of a
p o s s i b l eh e p a t o t o x i ca d v e r s er e a c t i o nt oC. racemosa herbal
extract to whom it was prescribed following our patterns.
Of our contact list 107 climateric women were followed-
up by telephone or direct clinical examination in our
department.
2.2. Study Protocol. Baseline characteristics of study partic-
ipants are available in Table 1. They were an heterogeneous
group of patients in diﬀerent phases of menopause and most
of them asked a complementary treatment for menopause
related anxiety and depression because of unsatisﬁed or
fear of synthetic drugs. Most of them were in good health,
but complaints referred to menopause. Only ﬁve patients
were suﬀering of chronic hepatobiliary disease (four patients
suﬀering of benign hepatic disease and one chronic toxic
hepatitis). We excluded from follow-up patients who had
suspended the treatment for more than 15 days, also
non-consecutive, or had spontaneously reduced the dose
prescribed.
We followed-up 107 women asking them by telephone
(33/107) and/or after clinical examination (74/107), to
undergo a blood sample examination to control main
laboratory parameters to evaluate liver function.
As shown in Table 2 patients underwent a blood sample
examination to evaluate: total leukocyte count, hepatic
transaminases, γ-glutamiltranspeptidase, alkaline phospa-
hatase, albumin, coagulation and total bilirubin. By tele-
phonethepatientswerequestionediftheywerestillregularly
consuming the herbal extract and they were asked some
question on the base of the same check-list used during
clinical examination in hospital.
3. Results
In all the patients (comprehending four patients suﬀering
of benign hepatic disease and one suﬀering of chronic toxicEvidence-Based Complementary and Alternative Medicine 3
Table 1: Baseline characteristics of study participants.
Characteristics N = 107 (%)
Age 48 (SD 4.24)
Menopause
Spontaneous premature 7 (6.5)
Perimenopause 29 (27.1)
Menopause from >3 years 55 (51.4)
Menopause from >6 years 10 (9.3)
Surgical menopause 6 (5.6%)
Treatment
Cimicifuga racemosa herbal extract titrated in 2.5% of actein
500mg daily 49 (45.8)
500mg + other plants 33 (30.9)
1000mg daily 11 (10.3)
1000mg + other plants 14 (13)
Clinical history
Depression or anxiety 89 (83.1)
Moderate alcohol consumption 86 (80.3)
Chronic headaches 27 (25.2)
Dyspepsia 16 (15)
Hypertension 12 (11.2)
Thyroid disease 8 (7.4)
Hepatobiliary disease 5 (4.6)
Allergies 5 (4.6)
Previous cancer non genital organ 3 (2.8)
Major heart disease 2 (1.8)
Autoimmunity disease 1 (0.93)
Major psychiatric diseases 0
Alcohol abuse 0
Previous idiosyncratic reactions to drugs 0
Concomitant medication
Antacids 26 (24.3)
NSAID 25 (23.3)
HRT 17 (15.9)
Hypotensive 12 (11.2)
Hormone thyroid therapy 8 (7.5)
Botanicals 5 (4.6)
Administration of blood product 0
Antiestrogen drugs 0
Vitamins 0
hepatitis) there were no sign of hepatic disease neither
alteration of plasma hepatic parameters, or worsening of
already altered but stable parameters. Only nine patients
were suﬀering of minor transient complaints (see Figure 2)
and after 1 month underwent by telephone a new follow-
up with a blood sample control that was negative for any
disease.
To our patients we administered very high doses respect
to median dose used in clinical trials (median range 40–
80mg daily) [7, 8], but after 12 months of regular use there
were no laboratory data, neither clinical signs, referring to a
possible hepatic adverse reaction.
Table 2: Follow up of patients assuming Cimicifuga.
Parameter Values
Physical examination
BMI 28.5 (SD 0.71)
Blood pressure
systolic 125 (SD 7.07)
diastolic 75 (SD 21.21)
Heart rate 76.5 (SD 0.71)
Few patients (9/107) were suﬀering of minor complaints, that
revalued after 1 month did not show any sign of liver disease
Abdominal pain 5 (4.6%)
Paresthesias 3 (2.8%)
Fatigue 2 (1.8%)
Anorexia 1 (0.9%)
Myalgia 1 (0.9%)
Malaise 1 (0.9%)
Pruritus 1 (0.9%)
Fever 0
Skin rash 0
Jaundice 0
Laboratory ﬁndings
Leukocyte total count 4250mm3 (SD 1060)
Bilirubin 0.75mgdl−1 (SD 0.07)
AST 29.5IU−1 (SD 10.61)
ALT 15.5IU l−1 (SD 17.68)
Alkaline Phosphatase 135 U l−1 (SD 63.64)
GGT 28 U l−1 (SD 7.07)
Albumin 3.75 gdl−1 (SD 0.49)
INR 1 (SD 0.14)
Few patients (9/107) were suﬀering of minor complaints,
like fatigue, aspeciﬁc abdominal pain and paresthesias,
(Table 2), controlled again after 1 month did not show any
sign of liver disease.
4. Discussion
4.1. Hepatotoxic Drug Reactions. Between 0.1 and 3% of all
hospital admissions are related to drug toxicity, but it is
suspected that many cases are not recognized. Since liver is
central to the metabolic disposition of virtually all drugs,
drug-induced hepatic injury is a potential complication of
nearly every medication. Fortunately adverse hepatic drug
reactions are relatively uncommon in comparison with the
number of drug prescriptions. In majority of the cases,
hepatic drug reactions present as acute hepatitis, which
is usually reversible and relatively benign; however, the
spectrum of liver disease may range from mild biochemical
abnormalities to acute hepatic failure.
When a drug is found to cause even rare hepatotoxicity
but is used by millions, it may disproportionally be removed
fromthemarket,althoughthissubstanceisarealdangeronly
for few patients. And should be stressed that to incriminate4 Evidence-Based Complementary and Alternative Medicine
any drug in an episode of liver dysfunction is a diﬃcult step-
by-step process that requires: high degree of suspicion, com-
patible chronology, awareness of its hepatotoxic potential,
competentexclusionofalternativecausesofliverdamageand
the ability to detect the presence of subtle data that favors a
toxic etiology [9].
It is very important in the step-by-step process to
rule out other causes of liver injury including hepatic
infections, alcoholic and autoimmune hepatitis, biliary tract
disorders and hemodynamic based diseases [10]. Finally
genetic and metabolic disorders may produce liver injury
such as hemochromatosis and Wilson’s disease. Liver injury
in the absence of other known causes may be drug-related
and requires additional information, such as that obtained
through a careful drug history, in relation to the onset of
injury [10].
In respect to the hepatotoxic potential of screened drugs,
their potential for causing liver damage is not the same, and
almost all marketed medications have been incriminated in
incidences of hepatotoxicity [9, 11]; probably because the
mostimportantfactorforhepatotoxicityisgeneticvariability
[12]. Genetic polymorphisms have a strong inﬂuence on
drug metabolism and may increase the risk of hepatotoxicity
[13].
The main causative group of drugs, in a large cohort of
hepatotoxicity cases collected in the Spanish registry, were
antibiotics followed by non-steroidal anti-inﬂammatory
drugs [14]; and statins have been shown to cause elevations
of aminotrasferase levels and severe liver injury in animals;
w h i l ei nh u m a n ss u c he l e v a t i o n sa r ec o m m o nb u tr a r e l y
if ever, lead to clinically signiﬁcant hepatotoxicity [15]. All
drugs that are well known hepatotoxic, and well stable
in the market, thanks to their therapeutic advantages, as
such as paracetamol, one of main causes worldwide of
liver transplant, nevertheless sold over-the-counter in many
Western countries.
4.2. Safety of Black Cohosh in Experimental Trials. As t u d yin
vitro on HepG2 cells and in vivo on rats to evaluate potential
hepatotoxicity of C. racemosa; showed cytotoxic reactions in
vivo at concentrations of 75μgml −1; and signiﬁcant initial
mithocondrial swelling in rats fed with 100 and 300mgkg−1
daily of C. racemosa extract, while clear microvesicular
steatosis of the hepatocytes and fragmentation of the rough
endoplasmic reticulum at 1000mgkg−1 daily [16]. The
Authors conclude that toxicity is not clinically relevant for
most patients but may become important in patients with
underlying risk factors [16], as like as for any drug; moreover
a dose of 100mgkg−1 is very high and corresponds in a
woman of 50kg at 5g of extract daily.
Natural and synthetic estrogens are known to alter
hepatobiliary physiology, and certain genetically susceptible
women become icteric during pregnancy, when high serum
oestrogen levels are present. Although not all the mecha-
nisms responsible for hepatic injury produced by estrogens
are known, it is consistently reported that Black Cohosh
extracts and isolated compounds do not posses estrogenic
activity, regardless of source, extraction procedure, dose or
length of exposure [17].
Chronic toxicity was not observed in rats at a dose of
500mgkg−1 per day for 27 weeks or in dogs at 400mgkg−1
per day for 26 weeks [18]. Furthermore, a 40% 2-propanol
extract of Black Cohosh was negative in the Ames test [18].
In mice, the LD50 of a Black Cohosh extract was 7.7gkg−1
forintragastricadministrationand1.1gkg−1 forintravenous
administration [18].
4.3. Safety of Black Cohosh in Humans. In clinical trials only
minor adverse side eﬀects have been reported, including
nausea, vomiting, head-aches and dizziness: a review of eight
clinical trials concluded that extracts of the rhizome of C.
racemosa might be a safe alternative for women seeking
alternative estrogen replacement therapy [19].
Black Cohosh also contains several catechols, such as
caﬀeic acid, piscidic acid and fukiic acid esters that exhibit
some antioxidant properties, including fukinolic acid, cimi-
cifugic acid A and cimicifugic acid B [20]. Such catechols
could be of signiﬁcant concern in toxicology because of the
possibility that they could be activated, either metabolically
or chemically, to electrophilic quinones. The potential of
such quinones to cause toxicity and carcinogenesis is well
documented, and can occur via arylation of cellular proteins
and DNA or redox cycling leading to the formation of
reactive oxygen species such as the hydroxyl radical [21].
Nevertheless has been shown in six perimenopausal women
after administration of a single dose of either 32, 64 or
128mg of C. racemosa that no corresponding mercapturic
acids were found in the urine [22]. In a previous study,
potentialtoxicitywassuspectedbecausecatecholsfromBlack
Cohosh are activated to quinoid metabolites, but catechols
are not absorbed across the bowel [23].
In a recent trial on 351 randomized women, placebo
controlled, Black Cohosh both used as single substance and
mixed in multi herbs remedies after 12 month of treatment,
did not show any eﬀect on lipids, glucose, insulin and
ﬁbrinogen [24].
Instead an important issue about safety is probably the
interaction with synthetic drugs because of the interference
with the metabolic pathway of cytochrome P4503A4 [25],
a potential cause of important adverse reactions, especially
in patients assuming multi drug regimen therapies as con-
ﬁrmed by a recent work in which ethanol and isopropanol
extract induced inhibition of CYP1A2, 2C9, 2D6, 3A4.
To be added a case of cutaneous pseudolymphoma in a
patient assuming a commercial extract of C. racemosa has
been reported recently [26]; and a case of muscle damage
with asthenia, high levels of creatine phosphokinase and
lactate dehydrogenase following assumption of a dietary
supplement derived from C. racemosa has also been reported
[27].
4.4. The EMEA and HMPC Signal of Hepatic Toxicity.
The EMEA and the HMPC have been made aware of a
number of case reports of hepatotoxicity (liver injuries) in
patients using C. racemosa rhizome. Following review of all
available data, the HMPC considered that there is a potential
connectionbetweenherbalmedicinalproductscontainingC.Evidence-Based Complementary and Alternative Medicine 5
racemosa rhizome and hepatotoxicity on the base of 42 case
reports of hepatotoxicity, collected from European National
Competent Authorities (34 cases) as well as literature case
reports (8 cases). Of these, only 16 cases were considered
suﬃciently documented to allow the Committee to assess
if use of C. racemosa rhizome could be linked to the liver
injuries. As a result of the assessment, ﬁve cases were
excluded and seven cases were considered unlikely to be
related. In the remaining only four cases (two autoimmune
hepatitis, one hepatocellular liver injury and one fulminant
hepatic failure), there was a temporal association.
So there are very few cases well documented and few data
available, for a concrete decision about its suspected hep-
atotoxicity; and in many reports C. racemosa extracts were
mixed with many other substances so that was impossible to
get any reliable reference to the assumption of C. racemosa.
Besides, in the best four cases is not possible to evidence
a clear hepatotoxic relationship with the consumption of C.
racemosa extract:
(a) In case 28, as numbered in the EMEA statement,
(RUCAM Score 4) the only collected from European
national competent authorities, the adverse reaction
is considered possible but information on diﬀerential
diagnostic assessment were not available. The patient
was assuming 80mg of an unknown type of extract
daily,foranunknownperiodandwithoutdiﬀerential
diagnostic available.
(b) In this published case report (RUCAM score 3)
[28] the patient was a 54-year-old woman suﬀering
of hypothyroidism, ﬁbromyalgia, osteoarthritis and
depression that had taken 1000mg of Black Cohosh
(no description of extract or crude drug) daily
for several months. The patient was on ﬂuoxetine,
propoxyphene and paracetamol (a well known hep-
atotoxic substance) concomitantly and drinking two
glasses of wine in the evening. In the statement it is
written “that since there is no further information
on the herbal preparation, the case report is not
of great relevance in the assessment of cimicifuga-
related hepatotoxicity” [6].
(c) A 57-year-old multimorbid African American
woman [29] (RUCAM Score 7) with a history
of polymyositis had developed an autoimmune
hepatitis about 3 weeks after the ﬁrst intake of C.
racemosae rhizoma (brand and dose unknown; no
information if it was a combination product). After
cessation of the drug and starting a therapy with
steroids and azathioprine, the patient recovered.
T h ea u t o i m m u n eh e p a t i t i sc o u l dh a v eb e e na s
well a manifestation of a multisystem autoimmune
disease. According to the draft recommendations
of the Scientiﬁc Advisory Panel Subgroups on
Hepatotoxicity, the case could be classiﬁed as
idiosyncratic liver necrosis.
The causal relationship to Black Cohosh in the present
case was ﬁrst assessed as “unclassiﬁable” as information
providedconcerningthereactionwasregardedasincomplete
and contradictory, while the follow-up publication includes
more (although to some extent contradictory) therapy
information.
(a) This a well-documented case (RUCAM Score 6) [30].
The admitted amount was 500mg drug per day.
The reaction was described as hepatocellular, other
causes for acute hepatitis were excluded. The provi-
sional clinical diagnosis was autoimmune hepatitis.
Therapy was started with 60mg prednisone/day
for 5 weeks. Liver enzymes improved, but due
to worsening coagulopathy and encephalopathy the
patient underwent an orthotopic liver transplanta-
tion. In the explanted organ, histologically features
of acute hepatitis, ﬁbrous linkage of portal tracts and
cholestasis were seen after 5 weeks on corticosteroids.
Nevertheless in this case too, the exact content of
the remedy based on Black Cohosh is not known:
was it an extract or crude drug? Did it contain other
toxicsubstances?Heavymetals?Lateronnevertheless
Levitsky et al. [30] reported that the patient did
not drink, use drugs or take any other medication;
but in a US District Court proceeding the woman
testiﬁed that she regularly drank wine, and used
both prescribed and non-prescribed pharmaceuticals
[31].
4.5.TheProblematicsofHerbADRs. We would like to remark
that it is very important before an oﬃcial statement about
any adverse reaction referred to an herb based product to
know the brand, dose of substance assumed, type of extract,
content of possible contaminants (wrong plants, pesticides,
heavy metals and aﬂatoxins) [32, 33]. When needed to
establish a connection between herb consumption and an
adverse reaction, especially if liver related, the same rules
of conventional drugs can be followed [32] only if the case
reportdealwithasinglesubstanceofamedicinalplant;while
if it is a multiherb preparation a direct toxic connection with
only one herb cannot be correctly established, unless it is
a well known hepatotoxic substance for example, Teucrium
chamaedrys;o ri ti sc o n t a i n e di nav e r yh i g hr a t i or e s p e c tt o
other herbs. To date in our opinion paradoxically the EMEA
statement could be regarded as the proof the risk of Black
Cohosh hepatotoxicity is scarce, because actually there is not
any full proved case of hepatotoxicity reported in front of
millions of doses used yearly in the world (about 1500000
women are using C. racemosae extracts only in Europe) [34];
and its safety was already been suﬃciently established by the
fact that in over 3800 participants in clinical trials there were
no hepatotoxic reactions reported [5].
In our series of patients assuming daily a very high dose
of extract (much more than 40–80mg used in most clinical
trials and usually recommended) [7, 8, 23] for at least 12
months we did not ﬁnd any clinical or laboratory proof
of liver disease; but the ﬁve already suﬀering of chronic
liver disease, that maintained stable clinical and laboratory
parameters (Table 3).
In our series we had a relative low number of patients
(32/107) assuming contemporary synthetic drugs to exclude6 Evidence-Based Complementary and Alternative Medicine
Table 3: Follow up of ﬁve patients suﬀering from stable chronic liver disease.
Patients at
baseline and
control
1 Baseline 1 Control 2 Baseline 2 Control 3 Baseline 3 Control 4 Baseline 4 Control 5 Baseline 5 Control
Leukocyte 5780mm3 6300mm3 3990mm3 4100mm3 6700mm3 6900mm3 8000mm3 7450mm3 3450mm3 4500mm3
Tot bilirubin 1.4mgdl−1 1.3mgdl−1 0.9mgdl−1 0.9mgdl−1 0.7mgdl−1 0.6mgdl−1 0.2mgdl−1 0.3mgdl−1 0.4mgdl−1 0.5mgdl−1
AST 57IU l−1 67IU l−1 38IU l−1 39IU l−1 45IU l−1 46IU l−1 38IU l−1 42IU l−1 41IU l−1 33IU l−1
ALT 47IU l−1 52IU l−1 36IU l−1 33IU l−1 37IU l−1 35IU l−1 20IU l−1 18IU l−1 45IU l−1 42IU l−1
Alkaline
phosphatase
1 5 0Ul −1 156 U l−1 119 U l−1 1 1 8Ul −1 110 U l−1 105 U l−1 1 2 0Ul −1 122 U l−1 110 U l−1 80 U l−1
γGT 55 U l−1 59 U l−1 22 U l−1 2 5Ul −1 35 U l−1 32 U l−1 45 U l−1 44 U l−1 48 U l−1 35 U l−1
Albumin 3.5 gdl−1 3.6 gdl−1 4.1 gdl−1 4.2 gdl−1 3gd l −1 2.9 gdl−1 3.8 gdl−1 4gd l −1 4.2 gdl−1 4.4 gdl−1
INR 0.8 0.9 1.2 1.3 0.9 0.9 1.1 1.1 1 1.2
reliably an interference on hepatic metabolism, although
they did not report any signiﬁcant side eﬀect.
5. Conclusions
A reporting rate higher than the background rate is taken as
a “signal” of a possible causal relationship between the drug
and the event [35], but in the EMEA statement the reported
cases are so faintly circumstantiated that we think there is
no evidence for an oﬃcial signal. On the base of our data
(although a small series of patients, but assuming high doses
of C. racemosae extracts) and current literature, we think C.
racemosa rhizome herbal extract should be considered safe
concerning liver toxicity.
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